Rhön-Klinikum zum Rückkauf eingereicht

Asklepios Kliniken has submitted to the management board of RHÖN-KLINIKUM a request to resolve the transfer of minority shareholders’ stakes against appropriate cash compensation (squeeze-out). Asklepios indirectly holds more than 95% of the shares; the cash compensation will be determined on the basis of a company valuation and reviewed by a court-appointed expert. The resolution is expected to be passed at an extraordinary general meeting in January 2027 and will become effective upon registration in the commercial register. » Plus sur de.investing.com

RHÖN-KLINIKUM recorded group revenue of EUR 863.6 million, an EBITDA of EUR 57.0 million and a group profit of EUR 22.5 million in H1 2026; the number of patients treated increased by 9%. The group is investing selectively in modern medical technology, the expansion of regional care networks and new collaborations. For 2026 the company cites revenue of around EUR 1.7 billion (±5%) and expects EBITDA between EUR 110 million and EUR 125 million, but sees significant uncertainties due to recent hospital and statutory health insurance (GKV) reforms and volatile conditions. » Plus sur finanzen.net

RHÖN-KLINIKUM closed 2025 with group revenue of EUR 1,704.7 million (+6.8% organically) and 938,650 patients treated. EBITDA fell slightly to EUR 105.9 million, and group profit declined to EUR 36.3 million, weighed down by higher depreciation and impairments. The supervisory board and executive board propose a dividend of EUR 0.20 per share; for 2026 revenue of around EUR 1.7 billion (+/-5%) and EBITDA of EUR 110–125 million are expected. » Plus sur finanzen.net